A desert tree for macular degeneration? A critical review finds cell data only — no animal or human proof

Watchdog coverage usually targets marketers who overstate evidence. This time the corrective comes from inside the literature: researchers at the University of Sonora published a preparation- and source-specific critical appraisal of Terminalia buceras (syn. Bucida buceras) for dry age-related macular degeneration (dAMD), carefully separating what has actually been measured from what has merely been proposed by analogy.

What evidence actually exists for this tree?

The review sorts the literature into five tiers, from species-specific chemistry down to hypothesis-generating comparisons with other plants. The direct retinal tier contains in-vitro work only: partial cytoprotection in ARPE-19 retinal cells under hydrogen-peroxide oxidative injury. Non-retinal findings (anti-inflammatory effects in other systems) concern different preparations, and isolated-compound studies of chemicals also found in other species are context, not evidence about this tree. Phytochemical standardization, eye exposure, metabolism and retinal bioavailability are all uncharacterized.

What does the review explicitly refuse to claim?

That T. buceras prevents or treats dAMD, modifies geographic atrophy, preserves visual function, or rivals approved care. For calibration, the review notes what proven therapies look like: complement inhibitors pegcetacoplan and avacincaptad pegol slowed geographic-atrophy lesion growth by roughly 14–22% in large trials — anatomical slowing, not restored vision, with real injection risks — and AREDS2 supplementation helps only defined risk groups. Against that bar, a cell-culture signal is a starting point for research, not a product claim.

How should readers use a review like this?

As a template for every botanical eye-health pitch: ask which tier the evidence sits in (human trial, animal model, cells, or analogy to other plants), whether the preparation sold matches the preparation studied, and whether the seller's language outruns the paper's own conclusions. Here the paper's own conclusion is that the findings do not establish a disease-modifying effect, clinically achievable retinal exposure, or chronic eye safety. Any marketing that says otherwise is contradicting its own source.

Where the evidence stands

• Established: Dry AMD involves oxidative stress, mitochondrial dysfunction and RPE failure; approved geographic-atrophy drugs slow lesion growth modestly without restoring vision, and AREDS2 helps only defined risk groups.
• Preliminary: Per a critical review (International Journal of Molecular Sciences, Oct 19, 2026), species-specific retinal evidence for Terminalia buceras is limited to partial cytoprotection in an ARPE-19 oxidative-injury cell model; chemistry is class-level and ocular exposure uncharacterized.
• Absent: Epidemiological studies, validated animal efficacy studies and clinical studies of T. buceras for AMD — the review states none exist.